2019
DOI: 10.1007/s00262-019-02413-w
|View full text |Cite
|
Sign up to set email alerts
|

Contribution of Fcγ receptor IIB to creating a suppressive tumor microenvironment in a mouse model

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
3
1
1

Citation Types

0
8
0

Year Published

2020
2020
2023
2023

Publication Types

Select...
5
1

Relationship

1
5

Authors

Journals

citations
Cited by 7 publications
(8 citation statements)
references
References 37 publications
0
8
0
Order By: Relevance
“…Indeed, targeted disruption of inhibitory FcRs is a relatively new and promising approach to enhance ADCP therapeutically. [49][50][51] Nevertheless, additional investigations are required to definitively establish the role of FcgRIIb in hypophagia.…”
Section: Discussionmentioning
confidence: 99%
“…Indeed, targeted disruption of inhibitory FcRs is a relatively new and promising approach to enhance ADCP therapeutically. [49][50][51] Nevertheless, additional investigations are required to definitively establish the role of FcgRIIb in hypophagia.…”
Section: Discussionmentioning
confidence: 99%
“…Alterations in the APP are known to be associated with immune evasion and can result in impaired antitumor responses and therapy resistance 45 . Additionally, the blockade of the interaction between the inhibitory Fc receptor FcγRIIB and immune complexes in mouse models has been proposed as an approach for cancer immunotherapy 46 . Thus, we identified immune cell players and components of specific pathways that can be further targeted to enhance the immunogenicity in HNSCC or that can be explored as markers of immunotherapy resistance.…”
Section: Discussionmentioning
confidence: 99%
“…Alterations in the APP are known to be associated with immune evasion and can result in impaired antitumor responses and therapy resistance (Gettinger et al, 2017;Sade-Feldman et al, 2017). Additionally, blockade of the interaction between the inhibitory Fc receptor FcγRIIB and immune complexes in mouse models has been proposed as an approach for cancer immunotherapy (Kasahara et al, 2019). Thus, we identified immune cell players and components of specific pathways that can be further targeted to enhance the immunogenicity in HNSCC or that can be further explored as markers of immunotherapy resistance.…”
Section: Discussionmentioning
confidence: 99%